Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 160   

Articles published

MRK 59.29 -0.12 (-0.20%)
price chart
Merck & Co., Inc. Stock Still Holding Its Position As A Big-Pharma Leader
Merck & Co. (NYSE: MRK) is the perfect example of a go-to �safe harbor� stock when market conditions turn bearish, as they did last Thursday and early Monday morning.
Related articles »  
Merck's Keytruda Effective In Fighting Stomach Cancer
Merck & Co., Inc. (MRK) yesterday, announced positive results from Phase I trials of its drug Keytruda, which was found to be effective in reducing tumor size in patients suffering from stomach cancer.
Merck & Co., Inc. (NYSE:MRK) Data On KEYTRUDA Monotherapy Indicates 31 ...  USMarketsDaily
Related articles »  
AstraZeneca Might Outperform Merck, Bristol-Myers In Cancer Therapy Market
It puts AstraZeneca in direct competition with Merck & Co., Inc. (MRK) and Bristol-Myers Squibb Co (BMY) for a share of the potential $34 billion immunotherapy market.
Related articles »  
Merck Reports Progress In Type-2 Diabetes Drug Trials
Merck is in the process of conducting a Phase III clinical trial program for omarigliptin, which will span 13 trials and involve 8,000 patients worldwide.
First data from phase 3 study of investigational once-weekly DPP-4 inhibitor ...
MSD Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an ...  Business Wire India (press release)
Related articles »  
Is it Time to Buy Merck & Co., Inc.'s Stock?
Investors in pharmaceutical giant Merck (NYSE: MRK ) have to be liking what they've witnessed in recent years as Merck's stock has vaulted to its highest levels since prior to the Great Recession. However, back Merck's chart out to a 15-year view and ...
Related articles »  
Fast Money Halftime Report Final Trade From September 26 - Merck & Co., Inc ...
CNBC Fast Money's Pete Najarian recommended a long position in Merck & Co., Inc. (NYSE: MRK). The stock traded 1.1 percent lower to around $59.
Is Merck & Co., Inc. A Leader In A Red Hot Market?
Merck & Co., Inc. (NYSE: MRK) stock has been on a steady incline for the most part since the 2009 bottom. With the stock now challenging 2007�2008 highs, will the underlying fundamentals be enough to incite an upside breakout?
Merck & Co., Inc. to Issue Quarterly Dividend of $0.44 on October 7th (MRK)  sleekmoney
BMO Capital Markets Raises Merck & Co. Price Target to $64.00 (MRK)  WKRB News
Related articles »  
Stocks to Watch: Merck & Co., Inc. (NYSE:MRK), Perrigo Company plc Ordinary ...
Merck & Co., Inc. (NYSE:MRK) has presented data on the investigational use of pembrolizumab in PD-L1 positive, advanced urothelial cancer, also known as bladder cancer.
Related articles »  
Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb Co: Getting A ...
Merck & Co. Inc. (NYSE: MRK) got the go-ahead from U.S. regulators on Sept. 4 for a new kind of cancer drug aimed at releasing the body's immune system to combat tumors.
Related articles »  
Merck Announces Positive Phase III Results For Odanacatib; Drug's Safety ...
Merck & Co., Inc. (MRK) announced yesterday, positive results from Phase III trials of its drug odanacatib, used to treat osteoporosis in postmenopausal women.
Stock Update: Merck & Co Inc (NYSE:MRK) � Merck Announces Data from ...  Jutia Group
Merck Says Odanacatib Meets Primary Endpoints Phase 3 Fracture Outcomes ...  NASDAQ
Related articles »